Craigavon, United Kingdom
Craigavon, United Kingdom

Time filter

Source Type

Methods for selecting whether to administer an anti-angiogenic therapeutic agent to a subject include steps of measuring the expression levels of one or more biomarkers selected from Table 2 or Table 3 in a sample from the subject; assessing from the expression levels of the one or more biomarkers whether the sample from the subject is positive or negative for a biomarker signature, wherein if the sample is positive for the biomarker signature an anti-angiogenic therapeutic agent is contraindicated. Related prognostic methods and treatment methods are also provided. The invention is particularly applicable in ovarian and colorectal cancers.


Patent
ALMAC DIAGNOSTICS Ltd | Date: 2015-05-28

The present invention relates to a cancer sub-type. Provided are methods for determining clinical prognosis of a subject with cancer, selecting whether to administer an anti-angiogenic therapeutic agent to a subject with cancer and predicting responsiveness of a subject with cancer to an anti-angiogenic therapeutic agent. The methods are based on assessing from the expression level of biomarkers disclosed herein whether the cancer belongs to the sub-type. Companion methods of treating cancer and agents for use in treating cancer are also provided.


Grant
Agency: European Commission | Branch: H2020 | Program: MSCA-ITN-ETN | Phase: MSCA-ITN-2016 | Award Amount: 2.63M | Year: 2017

The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple omics technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.


Grant
Agency: European Commission | Branch: FP7 | Program: MC-IAPP | Phase: FP7-PEOPLE-2012-IAPP | Award Amount: 570.31K | Year: 2013

Classical pathologic parameters have been used to inform adjuvant clinical treatment choices for early breast cancer patients. There remain a significant number of patients however, who despite a reportedly favourable prognostic profile, experience metastatic disease. Elucidation of the mechanisms of tumour adaptability and the identification of predictive markers of early recurrence is the basis of personalized medicine. Work from our group has established the developmental protein HOXC11 as a powerful predictor of resistance to endocrine treatment in breast cancer patients .The aim of this project is to establish a joint industry-academia partnership to produce a commercially viable and clinically validated predictive assay/kit which based on the use of HOXC11 as a predictive biomarker of poor response to endocrine treatment in breast cancer patients.


Patent
ALMAC DIAGNOSTICS Ltd | Date: 2014-12-12

A method is provided for characterising and/or prognosing prostate cancer in a subject comprising determining the expression level of at least one of CREM, ERRFI1, SRSF5, PDK4, HJURP, PDRG1, TRPM3, PDE4D, FI2, ADAMTS1, ADAMTS9, B3GNT5, CD38, CEBPD, CENPF, DKK1, EMP1, F3, IL1R1, IL8, JUNB, KLFIO, KLF4, LDLR, LGALS3, LPARI, MALAT1, MTUS1, MYBPC1, NFIL3, NR4A3, OAT, PI15, PTGS2, RHOBTB3, RIN2, RNFT2, SELE, SLC15A2, SOCS2, SOCS3, SSTR1, ST6GAL1, TSC22D1, XBP1 and ZFP36 in a sample from the subject. The method may be used to predict the likelihood of metastasis. Also disclosed are methods for diagnosing and selecting treatment for prostate cancer, together with corresponding methods of treatment. Systems, kits and computer programs for performing the methods are also provided.


Grant
Agency: GTR | Branch: Innovate UK | Program: | Phase: Small Business Research Initiative | Award Amount: 2.27M | Year: 2013

The DDRD Breast Assay has been developed by Almac Diagnostics to help clinicians and patients decide on whether the use of chemotherapy may be an appropriate approach following surgery for early stage node negative breast cancer patients. Patients who are called “positive” are approximately 4 times less likely to have a relapse compared to patients who are called “negative” by the test. This type of information is extremely valuable to both clinicians and patients as it allows a much more informed decision to be made on whether an individual patient is likely to benefit from standard of care chemotherapy. During the course of this project the DDRD Breast Assay will undergo further analytical and clinically validation to gain CE marking. On approval from the MHRA, it will be launched in the UK private health market and a DDRD Breast Registry established. Suitable clinical validation, analytical validation, clinical utility and cost effectiveness evidence will be gathered to support a submission to NICE with a view to launching this test in the Public UK health market.


Patent
Almac Diagnostics Ltd | Date: 2016-01-20

Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.


Patent
Almac Diagnostics Ltd | Date: 2015-08-13

Methods and compositions are provided for the identification of a molecular diagnostic test for cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used in different cancer types and with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.


Patent
ALMAC DIAGNOSTICS Ltd | Date: 2014-09-09

Methods and compositions are provided for the identification of a molecular diagnostic test for lung cancer. The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with NSCLC are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.


Patent
ALMAC DIAGNOSTICS Ltd | Date: 2014-09-09

Methods and compositions are provided for the identification of a molecular diagnostic test for oesophageal adenocarcinoma (OAC). The test defines a novel DNA damage repair deficient molecular subtype and enables classification of a patient within this subtype. The present invention can be used to determine whether patients with OAC are clinically responsive or non-responsive to a therapeutic regimen prior to administration of any chemotherapy. This test may be used with different drugs that directly or indirectly affect DNA damage or repair, such as many of the standard cytotoxic chemotherapeutic drugs currently in use. In particular, the present invention is directed to the use of certain combinations of predictive markers, wherein the expression of the predictive markers correlates with responsiveness or non-responsiveness to a therapeutic regimen.

Loading Almac Diagnostics Ltd collaborators
Loading Almac Diagnostics Ltd collaborators